Viral-mediated overexpression of mutant huntingtin to model HD in various species

Neurobiology of Disease

Volumn 48, Issue 2, 2012, Pages 202-211

  Ruiz, Marta ^a,b   Déglon, Nicole ^a,b,c  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^b Molecular Imaging Research Center   (France)

^c University of Lausanne Medical Center   (Switzerland)

Author keywords

Disease modeling; Gene transfer; Huntington's disease; Viral vectors

Indexed keywords

HUNTINGTIN; LENTIVIRUS VECTOR; MUTANT PROTEIN; PARVOVIRUS VECTOR; POLYGLUTAMINE; VIRUS VECTOR;

AUTOSOMAL DOMINANT DISORDER; CAG REPEAT; CENTRAL NERVOUS SYSTEM DISEASE; CORPUS STRIATUM; CYTOLOGY; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE MODEL; GENE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENE TRANSFER; GENETIC ENGINEERING; HUMAN; HUNTINGTIN GENE; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; INHERITANCE; INVERTEBRATE; MAMMAL; MOTOR DYSFUNCTION; MUTANT; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIMATE; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOM; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; TRANSGENIC ANIMAL; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS RECOMBINANT; VIRUS STRAIN;

ANIMALS; CELL LINE; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; HUNTINGTON DISEASE; INVERTEBRATES; LENTIVIRUS; MAMMALS; NERVE TISSUE PROTEINS; PEPTIDES; VIRUSES;

EID: 84865569806     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.08.023     Document Type: Review

References (154)

1. Ahmed B.Y., et al. Efficient delivery of Cre-recombinase to neurons in vivo and stable transduction of neurons using adeno-associated and lentiviral vectors. BMC Neurosci. 2004, 5:4.
2. Alves S., et al. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease. Hum. Mol. Genet. 2008, 17:2071-2083.
3. Arango M., et al. CA150 expression delays striatal cell death in overexpression and knock-in conditions for mutant huntingtin neurotoxicity. J. Neurosci. 2006, 26:4649-4659.
4. Banasik M.B., McCray P.B. Integrase-defective lentiviral vectors: progress and applications. Gene Ther. 2010, 17:150-157.
5. Bates G.P., Hockly E. Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?. Curr. Opin. Neurol. 2003, 16:465-470.
6. Beal M.F., et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 1993, 13:4181-4192.
7. Benchoua A., et al. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol. Biol. Cell 2006, 17:1652-1663.
8. Benchoua A., et al. Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II. Hum. Mol. Genet. 2008, 17:1446-1456.
9. Blomer U., et al. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J. Virol. 1997, 71:6641-6649.
10. Brene S., et al. Expression of mRNAs encoding ARPP-16/19, ARPP-21, and DARPP-32 in human brain tissue. J. Neurosci. 1994, 14:985-998.
11. Brene S., et al. Regulation of GluR2 promoter activity by neurotrophic factors via a neuron-restrictive silencer element. Eur. J. Neurosci. 2000, 12:1525-1533.
12. Broekman M.L., et al. Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 2006, 138:501-510.
13. Brouillet E., et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:7105-7109.
14. Brouillet E., et al. Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 1999, 59:427-468.
15. Burger C., et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. 2004, 10:302-317.
16. Cannon J.R., et al. Pseudotype-dependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra. Exp. Neurol. 2011, 228:41-52.
17. Cattaneo E., et al. Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 2005, 6:919-930.
18. Cearley C.N., Wolfe J.H. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol. Ther. 2006, 13:528-537.
19. Cearley C.N., Wolfe J.H. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J. Neurosci. 2007, 27:9928-9940.
20. Chamberlin N.L., et al. Recombinant adeno-associated virus vector: use for transgene expression and anterograde tract tracing in the CNS. Brain Res. 1998, 793:169-175.
21. Chan A.W., Yang S.H. Generation of transgenic monkeys with human inherited genetic disease. Methods 2009, 49:78-84.
22. Chao H., et al. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol. Ther. 2000, 2:619-623.
23. Cicchetti F., Parent A. Striatal interneurons in Huntington's disease: selective increase in the density of calretinin-immunoreactive medium-sized neurons. Mov. Disord. 1996, 11:619-626.
24. Colin E., et al. Akt is altered in an animal model of Huntington's disease and in patients. Eur. J. Neurosci. 2005, 21:1478-1488.
25. Colin A., et al. Engineered lentiviral vector targeting astrocytes in vivo. Glia 2009, 57:667-679.
26. Cooper J.K., et al. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum. Mol. Genet. 1998, 7:783-790.
27. Crook Z.R., Housman D. Huntington's disease: can mice lead the way to treatment?. Neuron 2011, 69:423-435.
28. Cummings J.L. Behavioral and psychiatric symptoms associated with Huntington's disease. Adv. Neurol. 1995, 65:179-186.
29. Davidson B.L., et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3428-3432.
30. D'Costa J., et al. Lentiviral vectors in clinical trials: current status. Curr. Opin. Mol. Ther. 2009, 11:554-564.
31. de Almeida L.P., et al. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J. Neurosci. 2002, 22:3473-3483.
32. Déglon N., Aebischer P. Lentiviruses as vectors for CNS diseases. Curr. Top. Microbiol. Immunol. 2002, 261:191-209.
33. Déglon N., Hantraye P. Viral vectors as tools to model and treat neurodegenerative disorders. J. Gene Med. 2005, 7:530-539.
34. DiFiglia M., et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17204-17209.
35. Diguet E., et al. Normal aging modulates the neurotoxicity of mutant huntingtin. PLoS One 2009, 4:e4637.
36. Dodiya H.B., et al. Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol. Ther. 2010, 18:579-587.
37. Drouet V., et al. Sustained effects of nonallele-specific Huntingtin silencing. Ann. Neurol. 2009, 65:276-285.
38. Eberling J.L., et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008, 70:1980-1983.
39. Escartin C., et al. Ciliary neurotrophic factor activates astrocytes, redistributes their glutamate transporters GLAST and GLT-1 to raft microdomains, and improves glutamate handling in vivo. J. Neurosci. 2006, 26:5978-5989.
40. Escartin C., et al. Activation of astrocytes by CNTF induces metabolic plasticity and increases resistance to metabolic insults. J. Neurosci. 2007, 27:7094-7104.
41. Faideau M., et al. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum. Mol. Genet. 2010, 19:3053-3067.
42. Farson D., et al. A new-generation stable inducible packaging cell line for lentiviral vectors. Hum. Gene Ther. 2001, 12:981-997.
43. Federoff H.J., et al. Expression of nerve growth factor in vivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:1636-1640.
44. Ferrante R.J., et al. Selective sparing of a class of striatal neurons in Huntington's disease. Science 1985, 230:561-563.
45. Ferrante R.J., et al. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res. 1987, 411:162-166.
46. Franich N.R., et al. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol. Ther. 2008, 16:947-956.
47. Furth P.A., et al. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:9302-9306.
48. Geller A.I., Breakefield X.O. A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science 1988, 241:1667-1669.
49. Glover C.P., et al. Adenoviral-mediated, high-level, cell-specific transgene expression: a SYN1-WPRE cassette mediates increased transgene expression with no loss of neuron specificity. Mol. Ther. 2002, 5:509-516.
50. Gomez-Tortosa E., et al. Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann. Neurol. 2001, 49:29-34.
51. Gradinaru V., et al. Optical deconstruction of parkinsonian neural circuitry. Science 2009, 324:354-359.
52. Gray M., et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 2008, 28:6182-6195.
53. Group, H.S. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov. Disord. 1996, 11:136-142.
54. Group, T.H.s.D.C.R. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983.
55. Hantraye P., et al. A primate model of Huntington's disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp. Neurol. 1990, 108:91-104.
56. Hantraye P., et al. Intrastriatal transplantation of cross-species fetal striatal cells reduces abnormal movements in a primate model of Huntington disease. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:4187-4191.
57. Harper S.Q., et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5820-5825.
58. Hodgson J.G., et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999, 23:181-192.
59. Hollis E.R., et al. Efficient retrograde neuronal transduction utilizing self-complementary AAV1. Mol. Ther. 2008, 16:296-301.
60. Horellou P., et al. Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. Neuroreport 1994, 6:49-53.
61. Huang B., et al. Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion. J. Gene Med. 2008, 10:269-279.
62. Hult S., et al. Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits. Cell Metab. 2011, 13:428-439.
63. Jackson G.R., et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 1998, 21:633-642.
64. Jakobsson J., et al. Targeted transgene expression in rat brain using lentiviral vectors. J. Neurosci. Res. 2003, 73:876-885.
65. Jakobsson J., et al. Lesion-dependent regulation of transgene expression in the rat brain using a human glial fibrillary acidic protein-lentiviral vector. Eur. J. Neurosci. 2004, 19:761-765.
66. Kaplitt M.G., et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 1994, 8:148-154.
67. Kaplitt M.G., et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007, 369:2097-2105.
68. Kato S., et al. Efficient gene transfer via retrograde transport in rodent and primate brains using a human immunodeficiency virus type 1-based vector pseudotyped with rabies virus glycoprotein. Hum. Gene Ther. 2007, 18:1141-1151.
69. Kato S., et al. A lentiviral strategy for highly efficient retrograde gene transfer by pseudotyping with fusion envelope glycoprotein. Hum. Gene Ther. 2011, 22:197-206.
70. Kay M.A., et al. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. 2001, 7:33-40.
71. Kirik D., Bjorklund A. Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. Trends Neurosci. 2003, 26:386-392.
72. Kirik D., et al. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2884-2889.
73. Kistner A., et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:10933-10938.
74. Klages N., et al. A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol. Ther. 2000, 2:170-176.
75. Klawans H.L., et al. Presymptomatic and early detection in Huntington's disease. Ann. Neurol. 1980, 8:343-347.
76. Kornum B.R., et al. Adeno-associated viral vector serotypes 1 and 5 targeted to the neonatal rat and pig striatum induce widespread transgene expression in the forebrain. Exp. Neurol. 2010, 222:70-85.
77. Kowall N.W., et al. Substance P and substance P receptor histochemistry in human neurodegenerative diseases. Regul. Pept. 1993, 46:174-185.
78. Kuhn A., et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet. 2007, 16:1845-1861.
79. Langbehn D.R., et al. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin. Genet. 2004, 65:267-277.
80. Lawlor P.A., et al. Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels. Mol. Neurodegener. 2007, 2:11.
81. Lawrence A.D., et al. Executive and mnemonic functions in early Huntington's disease. Brain 1996, 119(Pt 5):1633-1645.
82. Le Gal La Salle G., et al. An adenovirus vector for gene transfer into neurons and glia in the brain. Science 1993, 259:988-990.
83. Levine M.S., et al. Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 1999, 58:515-532.
84. Lim S.T., et al. Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS. Pharmacol. Res. 2010, 61:14-26.
85. Lin C.H., et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet. 2001, 10:137-144.
86. Liu Y.F. Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. J. Biol. Chem. 1998, 273:28873-28877.
87. Lobsiger C.S., Cleveland D.W. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat. Neurosci. 2007, 10:1355-1360.
88. Lombardi M.S., et al. A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp. Neurol. 2009, 217:312-319.
89. Lundberg C., et al. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr. Gene Ther. 2008, 8:461-473.
90. Lunkes A., Mandel J.L. A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum. Mol. Genet. 1998, 7:1355-1361.
91. Lunkes A., et al. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol. Cell 2002, 10:259-269.
92. Mandel R.J., et al. Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol. Ther. 2006, 13:463-483.
93. Manfredsson F.P., Mandel R.J. The development of flexible lentiviral vectors for gene transfer in the CNS. Exp. Neurol. 2011, 229:201-206.
94. Mangiarini L., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
95. Manilla P., et al. Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum. Gene Ther. 2005, 16:17-25.
96. Marks W.J., et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010, 9:1164-1172.
97. Martin E., et al. Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter. Hum. Mol. Genet. 2011, 20:2422-2434.
98. Mayford M., et al. Control of memory formation through regulated expression of a CaMKII transgene. Science 1996, 274:1678-1683.
99. Mazarakis N.D., et al. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum. Mol. Genet. 2001, 10:2109-2121.
100. McBride J.L., et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:5868-5873.
101. McCown T.J., et al. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res. 1996, 713:99-107.
102. McGeer E.G., McGeer P.L. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 1976, 263:517-519.
103. Menalled L.B. Knock-in mouse models of Huntington's disease. NeuroRx 2005, 2:465-470.
104. Menalled L.B., et al. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J. Neurosci. 2002, 22:8266-8276.
105. Miller V.M., et al. Allele-specific silencing of dominant disease genes. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:7195-7200.
106. Mittoux V., et al. Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. Hum. Gene Ther. 2000, 11:1177-1187.
107. Munoz-Sanjuan I., Bates G.P. The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. J. Clin. Invest. 2011, 121:476-483.
108. Myers R.H., et al. De novo expansion of a (CAG)n repeat in sporadic Huntington's disease. Nat. Genet. 1993, 5:168-173.
109. Naldini L., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263-267.
110. Palfi S., et al. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J. Neurosci. 1996, 16:3019-3025.
111. Palfi S., et al. Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates. Mol. Ther. 2007, 15:1444-1451.
112. Pardo R., et al. Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421. J. Neurosci. 2006, 26:1635-1645.
113. Park I.H., et al. Disease-specific induced pluripotent stem cells. Cell 2008, 134:877-886.
114. Passini M.A., et al. Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice. J. Virol. 2003, 77:7034-7040.
115. Perrin V., et al. Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease. Mol. Ther. 2007, 15:903-911.
116. Perrin V., et al. Implication of the JNK pathway in a rat model of Huntington's disease. Exp. Neurol. 2009, 215:191-200.
117. Petersen A., et al. Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. Hum. Mol. Genet. 2001, 10:1243-1254.
118. Pfeifer A., et al. Delivery of the Cre recombinase by a self-deleting lentiviral vector: efficient gene targeting in vivo. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:11450-11455.
119. Pfister E.L., et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr. Biol. 2009, 19:774-778.
120. Portales-Casamar E., et al. A regulatory toolbox of MiniPromoters to drive selective expression in the brain. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:16589-16594.
121. Regulier E., et al. Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum. Hum. Mol. Genet. 2003, 12:2827-2836.
122. Rodriguez-Lebron E., et al. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol. Ther. 2005, 12:618-633.
123. Roitberg B.Z., et al. Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease. Neurosurgery 2002, 50:137-145. discussion 145-6.
124. Ross C.A., Tabrizi S.J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011, 10:83-98.
125. Runne H., et al. Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry. J. Neurosci. 2008, 28:9723-9731.
126. Saudou F., et al. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998, 95:55-66.
127. Scammell T.E., et al. Focal deletion of the adenosine A1 receptor in adult mice using an adeno-associated viral vector. J. Neurosci. 2003, 23:5762-5770.
128. Schambach A., Baum C. Clinical application of lentiviral vectors-concepts and practice. Curr. Gene Ther. 2008, 8:474-482.
129. Schilling G., et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 1999, 8:397-407.
130. Senut M.C., et al. Intraneuronal aggregate formation and cell death after viral expression of expanded polyglutamine tracts in the adult rat brain. J. Neurosci. 2000, 20:219-229.
131. Shao J., et al. Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation. Mol. Cell. Biol. 2008, 28:5196-5208.
132. Shelbourne P.F., et al. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum. Mol. Genet. 1999, 8:763-774.
133. Slow E.J., et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 2003, 12:1555-1567.
134. Sondhi D., et al. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol. Ther. 2007, 15:481-491.
135. Tanaka Y., et al. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin. Neurobiol. Dis. 2006, 21:381-391.
136. Taymans J.M., et al. Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum. Gene Ther. 2007, 18:195-206.
137. Tobin A.J., Signer E.R. Huntington's disease: the challenge for cell biologists. Trends Cell Biol. 2000, 10:531-536.
138. Trettel F., et al. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 2000, 9:2799-2809.
139. Tuszynski M.H., et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 2005, 11:551-555.
140. van Bilsen P.H., et al. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum. Gene Ther. 2008, 19:710-719.
141. Van der Perren A., et al. Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9. Gene Ther. 2011, 18:517-527.
142. Vonsattel J.P., et al. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44:559-577.
143. Walker F.O. Huntington's disease. Lancet 2007, 369:218-228.
144. Wang L.H., Qin Z.H. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies. Acta Pharmacol. Sin. 2006, 27:1287-1302.
145. Wang C., et al. Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain. Gene Ther. 2003, 10:1528-1534.
146. Wheeler V.C., et al. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet. 1999, 8:115-122.
147. White E., et al. Evaluation and optimization of the administration of recombinant adeno-associated viral vectors (serotypes 2/1, 2/2, 2/rh8, 2/9, and 2/rh10) by convection-enhanced delivery to the striatum. Hum. Gene Ther. 2011, 22:237-251.
148. Wong L.F., et al. Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol. Ther. 2004, 9:101-111.
149. Xia H., et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 2004, 10:816-820.
150. Yamamoto A., et al. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000, 101:57-66.
151. Yang S.H., et al. Towards a transgenic model of Huntington's disease in a non-human primate. Nature 2008, 453:921-924.
152. Zala D., et al. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment. Neurobiol. Dis. 2005, 20:785-798.
153. Zuccato C., et al. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 2010, 90:905-981.
154. Zufferey R., et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 1998, 72:9873-9880.